Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
about
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.
P2860
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@en
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@nl
type
label
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@en
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@nl
prefLabel
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@en
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@nl
P2860
P356
P1476
Comment on 'costs of managing ...... -α2a compared with sunitinib'.
@en
P2093
C Charbonneau
P2860
P2888
P304
1307-8; author reply 1309-10
P356
10.1038/SJ.BJC.6605886
P407
P577
2010-09-14T00:00:00Z